NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 31 percent on Thursday morning after the company announced first successful commercial formulation of Zyesami or aviptadil for intravenous use in COVID-19 patients.
The company said the original RLF-100 formulation and manufacturing method had only a few weeks of stability, leaving hospitals unable to stock in pharmacies, and leaving aviptadil out of consideration for national strategic stockpiles.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.